PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

Erica L. Mayer(Harvard University), Yue Ren(Dana-Farber Cancer Institute), Nikhil Wagle(Harvard University), Reshma Mahtani, X. Cynthia(Washington University in St. Louis), Angela DeMichele(University of Pennsylvania), Massimo Cristofanilli(Cornell University), Jane Meisel(Emory University), Kathy D. Miller(Indiana University School of Medicine), Yara Abdou(University of North Carolina at Chapel Hill), Elizabeth C. Riley(University of Louisville), Rubina Qamar(Aurora Health Care), Priyanka Sharma(University of Kansas Medical Center), Sonya Reid(Vanderbilt University Medical Center), Natalie Sinclair(Dana-Farber Cancer Institute), Meredith Faggen(Dana-Farber Cancer Institute), Caroline Block(Harvard University), Naomi Y. Ko(Boston Medical Center), Ann H. Partridge(Harvard University), Wendy Y. Chen(Harvard University), Michelle K. DeMeo(Dana-Farber Cancer Institute), Victoria Attaya(Dana-Farber Cancer Institute), Amanda Okpoebo(Dana-Farber Cancer Institute), Jillian Alberti(Dana-Farber Cancer Institute), Yuan Liu(Pfizer (United States)), Eric Gauthier(Pfizer (United States)), Harold J. Burstein(Harvard University), Meredith M. Regan(Harvard University), Sara M. Tolaney(Harvard University)
Journal of Clinical Oncology
March 21, 2024
Cited by 108

Abstract

PURPOSE Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor–positive/human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation of CDK4/6i with endocrine therapy beyond initial tumor progression or if the addition of checkpoint inhibitor therapy has value in this setting. METHODS The randomized multicenter phase II PACE trial enrolled patients with hormone receptor–positive/HER2– MBC whose disease had progressed on previous CDK4/6i and aromatase inhibitor (AI) therapy. Patients were randomly assigned 1:2:1 to receive fulvestrant (F), fulvestrant plus palbociclib (F + P), or fulvestrant plus palbociclib and avelumab (F + P + A). The primary end point was investigator-assessed progression-free survival (PFS) in patients treated with F versus F + P. RESULTS Overall, 220 patients were randomly assigned between September 2017 and February 2022. The median age was 57 years (range, 25-83 years). Most patients were postmenopausal (80.9%), and 40% were originally diagnosed with de novo MBC. Palbociclib was the most common previous CDK4/6i (90.9%). The median PFS was 4.8 months on F and 4.6 months on F + P (hazard ratio [HR], 1.11 [90% CI, 0.79 to 1.55]; P = .62). The median PFS on F + P + A was 8.1 months (HR v F, 0.75 [90% CI, 0.50 to 1.12]; P = .23). The difference in PFS with F + P and F + P + A versus F was greater among patients with baseline ESR1 and PIK3CA alterations. CONCLUSION The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor–positive/HER2– MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.


Related Papers